Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders

Nuclear Medicine Review

Volumn 9, Issue 2, 2006, Pages 147-153

  Gerasimou, George P ^a   Aggelopoulou, Theodora C ^a   Costa, Durval C ^b,c   Gotzamani Psarrakou, Anna ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b HPP Medicina Molecular SA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

I 123 DaTSCAN; I 123 IBZM; Molecular imaging; Movement disorders; PET; SPECT

Indexed keywords

3 METHYLSPIPERONE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER C 11; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER F 18; 6 FLUORODOPA F 18; ALTROPANE I 123; COCAINE C 11; CYSTEINE ETHYL ESTER TC 99M; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; EPIDEPRIDE; IOFLUPANE I 123; METHYLPHENIDATE C 11; N 3 IODOPROPEN 2 YL 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RACLOPRIDE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TETRABENAZINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN DEGENERATION; CLINICAL TRIAL; DEMENTIA; DIFFERENTIAL DIAGNOSIS; ESSENTIAL TREMOR; FOLLOW UP; HUMAN; ISOTOPE LABELING; LEWY BODY; MOLECULAR IMAGING; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; HUMANS; MOLECULAR PROBE TECHNIQUES; MOVEMENT DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34247597319     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Bernheimer H, Birkmayer W, Hornykiewitz O, Jelinger K, Seitleberger F. Brain dopamine damage and the syndromes of Parkinson and Huntington. J Neurol Sci 1973; 20: 415-455.
2. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse 1991; 9: 43-49.
3. Tanner CM, Hubble JP, Chan P. Epidemiology and genetics of Parkinson's disease, in: Watts RL, Koller WC (eds) Movement disorders. Mc Graw-Hill Publ, New York 1997: 137-152.
4. Larsen TA, Calne DB. Essential tremor. Clin Neuropharmacol 1983; 6: 185-206.
5. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age and Ageing 1999; 28: 99-102.
6. Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson's disease. Arch Neurol 2000; 57: 369-372.
7. Quinn N. Parkinsonism-recognition and differential diagnosis. BMJ 1995; 310: 447-452.
8. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in caudate nucleus. J Neurochem 1991; 56: 192-198.
9. 123I-FP-CIT SPECT. J Nucl Med 1999; 40: 753-761.
10. 18F-fluorodopa, an analogue of dopa, and its use in direct measurements of storage, degeneration and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 1978; 75: 464-467.
11. 3H-2β-carbomethoxy-3β-(4-fluorophenyl) tropane. Mol Pharmacol 1989; 36: 518-524.
12. Kung MP, Essman WD, Frederick D et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 1995; 20: 316-324.
13. Madras BK, Meltzer PC, Liang AY, Elmaleh DR, Babich J, Fischman AJ. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 1998; 29: 93-104.
14. Volkow ND, Fowler JS, Gatley SJ et al. PET evaluation of the dopamine system of the human brain. J Nucl Med 1996; 37: 1242-1256.
15. 11C-tetrabenazine and positron emission tomography. J Neurochem 1993; 60: 2315-2318.
16. Seeman P, Niznik H. Dopamine receptors and transporters in Parkinson's disease. FASEB J 1990; 4: 2737-2744.
17. 123I in humans. Eur J Nucl Med 1990; 16: 813-816.
18. 123I-epidepride: characterization of uptake in the human brain. J Neural Transm (Gen Sect) 1995; 101: 95-103.
19. Wagner HN, Burns HD, Dannals RF et al. Imaging DA receptors in the human brain by PET. Science 1983; 221: 1264-1266.
20. 18F-N-methylspiroperidol and PET. J Nucl Med 1986; 27: 1876-1882.
21. Hughes AJ, Ben-Shlomo W, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-1146.
22. Kish SJ, Shannak K, Homykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 876: 876-880.
23. 18F-DOPA uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
24. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995; 45: 1995-2004.
25. 18F-DOPA PET findings on early Parkinson's disease. J Neurol Neurosurg Psych 1995; 59: 597-600.
26. Frost JJ, Rosier AJ, Reich SG et al. Positron emission tomography imaging of the dopamine transporter with C-11-Win 35,428 reveals marked declines in early Parkinson's disease. Ann Neurol 1993; 34: 423-431.
27. Wolters EC, Francot C, Bergmans P et al. Preclinical (pre-motor) diagnosis in Parkinson's disease. J Neurol 2000; 247 (S2): 103-109.
28. Berendse HW, Booij J, Francot Ch et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001; 50: 34-41.
29. Berendse HW, Booij J, Stoffers D et al. Presymptomatic detection of Parkinson's disease. Tijdschr Gerontol Geriatr 2002; 33: 70-77.
30. Wolters EC, Francot C, Bergmans P et al. Preclinical (pre-motor) Parkinson's disease. J Neurol 2000; 247 (S2): 103-109.
31. 123I-β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
32. 123I-β-CIT single photon emission computed tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med 1997; 24: 1171-1174.
33. 123I-β-CIT SPECT. J Neurol 1998; 245: 14-20.
34. 123I-β-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson's disease. J Neurol Neurosurg Psych 1997; 62: 133-140.
35. Seibyl JP, Marek KI, Sheff K et al. Test/pretest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson's disease. J Nucl Med 1997; 38: 1453-1459.
36. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Communic 2005; 26: 421-426.
37. 123I-â-CIT SPECT demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
38. Ouchi Y, Yishikawa E, Okada H et al. Alterations in binding site density of dopamine transporters in the striatum, orbitofrontal cortex and amygdala in early Parkinson's disease: compartment analysis of β-CFT binding with positron emission tomography. Ann Neurol 1999; 45: 601-610.
39. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34: 423-431.
40. 18F-β-CFT, is reduced in early Parkinson's disease. Synapse 1999; 31: 119-124.
41. 123I-FP-CIT in healthy volunteers. Eur J Nucl Med 2000; 27: 867-869.
42. 123I-FP-CIT SPECT striatal uptake. Movement Disorders 2000; 15: 692-698.
43. 123I-β-CIT and SPECT correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm 1997; S50: 9-24.
44. 123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2006,33:87-92.
45. 99mTcTRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease. Eur J Nucl Med Mol Imaging 2004; 32: 302-307.
46. 123I-β-CIT in Parkinson's disease and progressive supranuclear palsy, evaluates by single-photon emission tomography. Eur J Nucl Med 1998; 25: 1270-1276.
47. Findley LJ, Büttner K. Tremor. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds) Neurological disorders: course and treatment. Academic Press: Inc, San Diego-New York-Boston-London-Sydney-Tokyo-Toronto 1996: 853-860.
48. Gertel WH, Gerstner A. The differential diagnosis of Parkinson's syndrome and essential tremor. Eur J Neurol 2000; 7 (S3): 177-178.
49. Rajput AH, Rozdisky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci 1991; 18: 272-278.
50. Asenbaum S, Brücke T, Pirker W et al. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997; 38: 1-6.
51. 18F-dopa PET study. Neurology 1992; 42: 1554-1560.
52. 123I-FP-CIT Study Group. Movement Disorders 2000; 15: 503-510.
53. 123I-β-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105: 1211-1213.
54. 123I-FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266-272.
55. 123I-loflupane in the differential diagnosis of Parkinsonism and essential tremor. Hell J Nucl Med 2005; 8: 81-65.
56. 123I-loflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Movement Disorders 2004; 19: 1175-1182.
57. O'Sullivan JD, Costa DC, Gacinovic S, Lees AJ. SPECT imaging of the dopamine transporter in juvenile-onset dystonia. Neurology 2001; 56: 266-267.
58. 123I-FP-CIT SPECT. Schizophrenia Research 2001; 47: 59-67.
59. Lavalaye J, Sarlet A, Booij J et al. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. Psychopharmacology 2001; 155: 107-109.
60. Costa DC, Walker LWH, Walker S, Gacinovic S, Janssen AGM, Katona CLE. Dopamine transporter loss in dementia with Lewy bodies and Parkinson's disease compared with Alzheimer's disease and controls (abstract). J Nucl Med 1998; 39: 124.
61. Walker Z, Costa DC, Walker LWH et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psych 2002; 73: 134-140.
62. Costa DC, Walker Z, Walker R, Fontes F. Dementia with Lewy bodies versus Alzheimer's disease. Role of dopamine transporter imaging. Movement Disorders 2003; 18: S34-S38.
63. Walker Z, Costa DC, Walker R et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson's disease. A comparison. Neurology 2004; 62: 1568-1572.
64. Walker Z, Costa DC, Ince P, McKeith IG, Katona CLE. In vivo demonstration of dopamine degeneration in dementia with Lewy bodies. The Lancet 1999; 354: 646-647.
65. 123I-β-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity. Neurol. Res 1999; 21: 255-261.
66. Robertson MM. Annotation: Gilles de la Tourette syndrome-an update. J Child Psychol Psychiatry 1994; 35: 597-611.
67. 123I-FP-CIT/SPECT study. Acta Psychiatr Scand 2004; 109: 140-146.
68. 2-like dopamine receptors in human brain. In: Niznik HB (ed) Dopamine receptors and transporters: pharmacology, structure and function. Marcel Dekker Inc, New York-Basel-Hong Kong 1994: 345-383.
69. Ichise M, Kim YJ, Ballinger JR et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-DOPA untreated PD. Neurology 1999; 52: 1206-1214.
70. 11C-raclopride positron emission tomography in previous untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2 receptors. Neurology 1994; 44: 1325-1329.
71. 123I-IBZM binding compared with long-term clinical follow-up in patients with de novo parkinsonism. Mov Disord 1998; 13: 16-19.
72. Hierholzer J, Cordes M, Venz S et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian-plus syndromes. J Nucl Med 1998; 39: 954-960.
73. 123I-IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047-1056.
74. 2 receptor SPECT. Eur Neurol 1995; 35: 50-54.
75. 2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11: 220-228.
76. Pirker W, Asenbaum S, Wenger S et al. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 1997; 38: 1711-1717.